Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Evolocumab (Repatha) vs Losartan: Evolocumab (Repatha) has the stronger overall evidence (4.5 vs 4.2/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Evolocumab (Repatha) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Evolocumab (Repatha) and Losartan have evidence — compare verdict strength side-by-side.
Standard approved dosing is 140 mg subcutaneously every 2 weeks OR 420 mg subcutaneously once monthly, under a clinician. A prescription drug; this is informational, not a recommendation.
any
Subcutaneous prefilled autoinjector (evolocumab)
Off-label longevity/muscle-aging use mirrors low antihypertensive dosing (25–100 mg once daily) under a clinician. Not an approved longevity or anti-sarcopenia regimen; blood pressure, kidney function, and potassium should be monitored.
any
Oral tablet (losartan potassium)
Weeks
Months to years
Weeks
Throughout use
Months to years
Years
Unknown in humans
Throughout use
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
The New England journal of medicine (2017) · Rct · n=27564
FOURIER randomized ~27,564 patients with atherosclerotic cardiovascular disease on statin therapy
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
Circulation (2022) · Open label
FOURIER-OLE: open-label extension following patients on long-term evolocumab
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
JAMA (2016) · Rct
GLAGOV randomized statin-treated patients to evolocumab or placebo with serial intravascular ultrasound
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet (London, England) (2002) · Rct · n=9193
LIFE randomized trial in hypertensives with left-ventricular hypertrophy
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
The New England journal of medicine (2001) · Rct · n=1513
RENAAL randomized, double-blind trial in type-2 diabetic nephropathy
Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia.
Science translational medicine (2011) · Animal
In sarcopenic mice, losartan reduced fibrosis and improved muscle function after injury
Evolocumab (Repatha) has a higher evidence score (4.5/10 vs 4.2/10) and wins in 2 of 3 categories.
For support heart health, Evolocumab (Repatha) has a higher relevance score (80 vs 66).
No known interactions between Evolocumab (Repatha) and Losartan have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.